SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma’s arm gets USFDA’s tentative approval for Triamcinolone Acetonide Ointment

24 Jan 2020 Evaluate

Strides Pharma Science’s step?down wholly owned subsidiary -- Strides Pharma Global Pte., Singapore, has received tentative approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA).

While it was amongst the few Competitive Generic Therapy (CGT) designated products for Strides, another generic company received approval prior to the company’s approval. Consequently, the final approval for Strides will be effective May 30, 2020 when the company will launch the product.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately $20 Mn. The product will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.  The company has 102 cumulative ANDA filings with USFDA of which 69 ANDAs have been approved and 33 are pending approval. 

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1128.00 6.50 (0.58%)
07-Jul-2026 14:42 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1905.00
Dr. Reddys Labs. 1366.10
Cipla 1457.20
Zydus Lifesciences 1154.00
Lupin 2480.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: